DOI: 10.12890/2025_005464

Unexpected falsely high vancomycin concentrations in a patient with endocarditis during routine therapeutic drug monitoring

Authors

  • Laura Galán-Caballero Department of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain
  • María del Rosario Salas-Butrón Department of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain; Department of Pharmacology and Toxicology, Universidad Complutense; IdISSC, Madrid, Spain
  • Daniel Lozano-Martín Department of Clinical Pharmacology, Central de la Defensa “Gómez Ulla” Hospital, Madrid, Spain
  • Iván Alejandro Díaz-Rengifo Department of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain
  • Isabel Ortega-Madueño Department of Clinical Analysis, Hospital Clínico San Carlos, Instituto de Medicina del Laboratorio, Madrid, Spain
  • Lucia Diaz-Garcia Department of Clinical Pharmacology, IdiPAZ, La Paz University Hospital, School of Medicine, Autonomous University of Madrid, Madrid, Spain
  • Ana Isabel Terleira-Fernández Department of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain; Department of Pharmacology and Toxicology, Universidad Complutense; IdISSC, Madrid, Spain

mariadelrosario.salas@salud.madrid.org

Keywords

Vancomycin, interference, immunoassay, therapeutic drug monitoring

Abstract

Introduction: Vancomycin is a glycopeptide antibiotic indicated for the treatment of infections caused by methicillin-resistant Staphylococcus aureus. Appropriate vancomycin therapeutic drug monitoring is an essential exercise to improve the achievement of the target therapeutic levels.
Case description: An 87-year-old female was admitted with diagnosis of endocarditis. She was started on antibiotic therapy with intravenous vancomycin. The first vancomycin level registered in our hospital was 36.4 µg/ml. Because this value exceeded the critical threshold (15–20 µg/ml) the prescription was interrupted. New vancomycin concentration tests were indicated for the next days with 65.8 µg/ml, 73 µg/ml, 55.1 µg/ml, 77.9 µg/ml and 100 µg/ml results. Two samples were reanalysed in Hospital Universitario La Paz and were undetectable. Our Clinical Analysis Department found an analytical interference; however, the responsible molecule could not be identified, so the clinical team changed antibiotic treatment to daptomycin, and the infectious condition of the patient improved.
Conclusions: It is recommended that clinicians have a high index of suspicion to investigate cases where drug concentrations do not correlate with clinical expectations. Healthcare professionals need to understand that occasional interference still occurs due to the binding of proteins.

View the entire article

Downloads

References

  1. Patel S, Preuss CV, Bernice F. Vancomycin. 2024; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
  2. Van Der Heggen T, Buyle FM, Claus B, Somers A, Schelstraete P, De Paepe P, et al. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm 2021;43:1394–1403. doi: 10.1007/s11096-021-01266-7
  3. Cheng X, Ma J, Su J. An overview of analytical methodologies for determination of vancomycin in human plasma. Molecules 2022;27:7319. doi: 10.3390/molecules27217319
  4. Tsoi V, Bhayana V, Bombassaro AM, Tirona RG, Kittanakom S. Falsely elevated vancomycin concentrations in a patient not receiving vancomycin. Pharmacotherapy 2019;39:778–782. doi: 10.1002/phar.2279
  5. Singer B, Stevens RW, Westley BP, Nicolau DP. Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. Am J Health Syst Pharm 2020;77:9–13. doi: 10.1093/ajhp/zxz258
  6. Rice ML, Go JR, Rivera CG, Zeuli JD, Saleh OA, Baumann NA, et al. Unexpected vancomycin pharmacokinetic profile secondary to macromolecular complexing: a case series. Ther Drug Monit 2021;43:696–700. doi: 10.1097/FTD.0000000000000888
  7. Smelter DF, Trisler MJ, McCreary EK, Baker M, Copeland K, Dilworth TJ, et al. Long-acting lipoglycopeptides can interfere with vancomycin therapeutic drug monitoring. J Clin Pharmacol 2022;62:472–478. doi: 10.1002/jcph.1975
  8. Simons SA, Molinelli AR, Sobhani K, Rainey PM, Hoofnagle AN. Two cases with unusual vancomycin measurements. Clin Chem 2009;55:578–580. doi: 10.1373/clinchem.2008.112946
  9. Westergreen-Thorne M, Lee SY, Shah N, Dodd A. When not to trust therapeutic drug monitoring. Oxf Med Case Reports 2016;2016:omw064. doi: 10.1093/omcr/omw064
  10. Tang NY, Walewski K, Carey-Ballough R, Sykes E, Sun Q. A suspected case of falsely low digoxin and vancomycin concentrations caused by free kappa light chains with PETINIA method. Pract Lab Med 2022;30:e00277. doi: 10.1016/j.plabm.2022.e00277
  11. Elzieny M, Fisher JA, Sims MD, Lauter CB, Carey-Ballough RA, Sun Q. Falsely decreased vancomycin caused by rheumatoid factor: a case report. Clin Chim Acta 2023;548:117460. doi: 10.1016/j.cca.2023.117460
  12. Pokhriyal SC, Tan EFS, Bhatt PK, Khan AA, Pasha MN, Pierre L, et al. Assay interference causing persistently elevated vancomycin levels leading to treatment failure and fatal outcome. Cureus 2024;16:e61943. doi: 10.7759/cureus.61943

Published

2025-06-09

How to Cite

1.
Galán-Caballero L, Salas-Butrón M del R, Lozano-Martín D, Díaz-Rengifo IA, Ortega-Madueño I, Diaz-Garcia L, et al. Unexpected falsely high vancomycin concentrations in a patient with endocarditis during routine therapeutic drug monitoring. EJCRIM [Internet]. 2025 June 9 [cited 2026 Nov. 18];12(7). Available from: https://ojs.wedare.app/ejcrim/article/view/5464